| GTO ID | GTC2219 |
| Trial ID | NCT04139057 |
| Disease | Head and Neck Squamous Cell Carcinoma |
| Altered gene | EBV |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | EBV TCR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | Single-Arm Trial of EBV-Specific TCR-T Cells With Anti-PD1 Auto-secreted Element in the Treatment of EBV-Positive Head and Neck Carcinoma |
| Year | 2019 |
| Country | China |
| Company sponsor | Xinqiao Hospital of Chongqing |
| Other ID(s) | XQDC20191001 |
| Cohort 1 | |||||||
|
|||||||